Get started
Work

[Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain

Year: 2025
Type: article
Abstract: INTRODUCTION: Heart failure is an increasingly common syndrome with a rising prevalence, which associates significant costs, mainly related to hospitalization. In fact, heart failure is the most frequent diagnosis in hospital discharges in Spain. OBJECTIVE: To analyze the economic impact of new treatments for heart failure with reduced ejection fraction such as sacubitril/valsartan in out-patient and in-patient setting. MATERIAL AND METHODS: The present economic evaluation study was carried out by developing a Markov model. Treatment with sacubitril/valsartan from admission or after hospital discharge was compared, with enalapril being the comparator. Total costs, years of life gained, quality-adjusted life years, and incremental cost-effectiveness ratio and incremental cost-utility ratio were analyzed. Data were obtained from the PARADIGM-HF and PIONEER-HF studies. RESULTS: The results of the base cases of the three comparisons made showed that sacubitril/valsartan produced benefits in years of life gained and quality-adjusted life years compared to enalapril showing incremental cost-utility ratio below €20,000/QALY and that this ratio was better in scenarios starting sacubitril/valsartan in the hospital setting once decompensation was resolved. CONCLUSION: This study shows that starting sacubitril/valsartan from hospital admission for heart failure is cost-effective from the perspective of the National Health Service in Spain.
DOI: 10.1016/j.farma.2025.08.004
Authors: Antonio García-Quintana, Héctor Alonso Ramos, Javier Parrondo
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,640
OpenAlex ID: W4413420010
FWCI: 0.649
Cites: 14
Cited by: 1
Related to: 10